RECENT POSTS

31

May, 2019

National research team targets glioblastoma

By: | Tags: | Comments: 0

MAY 31, 2019 —  Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and is characterized by its infiltrative and often fatal progression. The strikingly poor survival for patients with GBM of 14-16 months following diagnosis is…

READ MORE

30

May, 2019

BIOMARK’S ABSTRACT FOR 2019 ASCO ONLINE PUBLICATION

By: | Tags: | Comments: 0

Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity. Sub-category: Circulating Biomarkers Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) Meeting: 2019 ASCO Annual Meeting Abstract No: e14536 Citation: J Clin Oncol 37, 2019 (suppl; abstr e14536) Author(s): Andrew W. Maksymiuk, Paramjit S. Tappia, Bram Ramjiawan, Nazrina Khatun, Rahnuma Parveen, Rashiduzzaman Ahmed, Gina Huang, Rashid Bux Ahmed, Parveen S. Akhtar, Horacio Bach, Daniel Sitar; CancerCare Manitoba, Winnipeg, MB, Canada; Asper Clinical Research…

READ MORE
Cancer risk in families

26

Mar, 2019

Cancer risk in families

By: | Tags: | Comments: 0

If you have family members with cancer, you may wonder if you are at risk of developing it too (if it “runs in the family”). Sometimes a gene mutation that can cause cancer is passed on to you by…

READ MORE
Glioblastoma Multiforme (GBM)

26

Mar, 2019

About Glioblastoma (GBM)

By: | Tags: | Comments: 0

Overview Tumour Group: Gliomas WHO Grade: Grade IV Prevalence/Incidence: The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours. GBMs increase in frequency with age, and affect more men than women. Typical Age Range: GBMs may manifest at any age, but mostly…

READ MORE